Re: TDM-1 results reported @ ASCO annual mtg 2012 now in New England Journal of Medic
Hi all
If you think the FDA is bad then NICE ( or nasty) here in England is terrible! The bean counters still won't fund lapatinib and I suspect T-DM1 and pertuzumab will have a big struggle also. This is such a shame for all those that need it and causes huge frustration for our breast oncologists who effectively have their hands tied.
Ellie
|